Orexigen Therapeutics Inc., of San Diego, said that the Korean Ministry of Food and Drug Safety has approved Contrave (naltrexone HCI and bupropion HCI extended release) monotherapy for weight management in overweight or obese adult patients. In anticipation of a commercial launch this quarter, the company has shipped an initial order of Contrave tablets to its partner there, Kwang Dong Pharmaceutical Co. Ltd.